Vimta Labs Q1FY27 PAT rises 11.4% to ₹210.42 Mn
Vimta Labs Limited reported a 13.7% year-on-year increase in total income to ₹1,128.86 Mn for Q1 FY27, with net profit rising 11.4% to ₹210.42 Mn. EBITDA improved to ₹283.38 Mn, expanding margins to 36.4%. Despite sequential margin compression due to facility costs and rupee appreciation, management maintained a 20-25% revenue growth target for the year. Operational highlights include the commencement of Biologics CRADS and a regulatory audit from Ukraine.
*this image is generated using AI for illustrative purposes only.
Vimta Labs Limited reported a year-on-year improvement in its financial performance for the first quarter ended June 30, 2026, with total income rising 13.7% to ₹1,128.86 Mn. Net profit increased 11.4% to ₹210.42 Mn from ₹188.94 Mn in the corresponding period of the previous year. The company's EBITDA stood at ₹283.38 Mn, with margins expanding to 36.4% from 35.7% in the year-ago period, driven by healthy traction in its Pharmaceutical Research and Testing Services business. The Board of Directors approved the unaudited financial results on July 20, 2026, with statutory auditors conducting a limited review.
Financial Performance
While Q1 revenue remained steady at ₹1,128.86 Mn, reflecting 13.7% year-on-year growth, operating margins declined on a quarter-on-quarter basis. Management attributed the sequential margin compression to higher facility costs, the implementation of new labour laws, and rupee appreciation. Despite these headwinds, the company has indicated it expects no further drop in margins going forward. The Food Testing division faced ongoing global uncertainties, which the business offset through deeper domestic market penetration.
The following table summarises the key financial metrics for Q1 on a year-on-year and quarter-on-quarter basis:
| Particulars (₹ Mn) | Q1 FY27 | Q4 FY26 | QoQ (%) | Q1 FY26 | YoY (%) |
|---|---|---|---|---|---|
| Total Income | 1,128.86 | 1,119.96 | 0.80% | 993.13 | 13.70% |
| EBITDA | 283.38 | 290.47 | -2.40% | 252.62 | 12.20% |
| EBITDA Margin | 36.40% | 37.60% | 35.70% | ||
| PAT | 210.42 | 211.13 | -0.30% | 188.94 | 11.40% |
| PAT Margin | 18.60% | 18.90% | 19.00% | ||
| Basic EPS | 4.71 | 4.73 | -0.50% | 4.25 | 11.00% |
Operational Highlights
The company operates through a single reportable segment, 'Contract Research and Testing Services'. During the quarter, Vimta Labs commenced operations in Biologics contract research and development services (CRADS) and secured its first domestic order for the new biologics facility. Management has indicated that the biologics facility is anticipated to significantly enhance revenue and margins starting in the third year. The company also successfully completed a regulatory audit from Ukraine during the quarter.
The Nomination and Remunerations Committee granted 40,500 stock options to eligible employees under the Vimta Labs Employee Stock Option Plan 2021. Revenue and costs included ₹0.45 million relating to lab setup services provided under a Service Concessionaire Arrangement with the Food Safety and Standards Authority of India (FSSAI). The employee benefits expense included ₹8.46 million for the quarter related to the stock option plan.
Management Outlook
Management has set an ambitious revenue growth target of 20% to 25% for the current financial year. The company expects strong inquiry trends and robust demand to boost performance in future quarters, particularly in the Pharma segment and a recovering Clinical Research business. Management also foresees business growth ahead and expects no further deterioration in margins despite the cost pressures experienced in Q1.
Earnings Call Recording
The audio recording of the Q1 FY 2026–27 Earnings Call held on July 20, 2026, is available on the company's website. The disclosure was made in compliance with Regulation 30 of the SEBI (LODR) Regulations, 2015.
Historical Stock Returns for Vimta Labs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.06% | +6.18% | +3.01% | +14.18% | +11.85% | +249.80% |
What is the expected timeline for securing international orders for the new Biologics CRADS facility?
How will the company mitigate the impact of rupee appreciation on margins in the coming quarters?
What specific strategies are in place to drive the projected 20-25% revenue growth for the full financial year?
18
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
